PAI-1 stability: the role of histidine residues  by Mångs, Helena et al.
PAI-1 stability: the role of histidine residues
Helena Mafings, Guang-Chao Sui1, Bjo«rn Wiman*
Department of Clinical Chemistry and Blood Coagulation, Karolinska Hospital, Karolinska Institute, S-171 76 Stockholm, Sweden
Received 12 April 2000; received in revised form 22 May 2000
Edited by Shmuel Shaltiel
Abstract The role of the 13 histidine residues in plasminogen
activator inhibitor 1 (PAI-1) for the stability of the molecule was
studied by replacing these residues by threonine, using site-
directed mutagenesis. The generated mutants were expressed in
Escherichia coli, purified and characterized. All variants had a
normal activity and formed stable complexes with tissue-type
plasminogen activator. Most of these PAI-1 variants displayed a
similar pH-dependency in stability as wild-type PAI-1, with
increased half-lives at lower pH. However, the variant
His364Thr had a half-life of about 50 min at 37‡C and had
almost completely lost its pH-dependency. Therefore, our data
suggest that His364, in the COOH-terminal end of the molecule
might be responsible for the pH-dependent stability of PAI-
1. ß 2000 Federation of European Biochemical Societies.
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1. Introduction
Plasminogen activator inhibitor 1 (PAI-1) is the physiolog-
ical inhibitor of tissue-type plasminogen activator (tPA) and
urokinase. In vivo, PAI-1 seems to be a major regulator of the
¢brinolytic system [1] and increased levels are correlated with
the development of thrombotic disease, principally myocardial
infarction [2,3] but also deep vein thrombosis [4,5] and stroke
[6]. PAI-1 is a member of the serine protease inhibitor super-
family of proteins and consists of a single polypeptide chain of
379 amino acid residues [7^9]. PAI-1 spontaneously converts
from the functionally active form into an inactive, so-called
latent form, with a half-life of about 2 h at neutral pH and
37‡C [10,11]. In plasma most of the active PAI-1 is bound to
vitronectin, resulting in an increased stability of about 4 h
[10,11]. The latent form of the inhibitor can be reactivated
by treatment with guanidinium chloride or urea in high con-
centrations, followed by dialysis at slightly acidic pH [12,13].
It has also been reported that vitronectin [14,15] and phos-
pholipid [16] slowly may reactivate latent PAI-1. During the
conversion to the latent form there is a complete insertion of
the reactive center loop (RCL) into L-sheet A [17]. It has been
found that substitution of residues in di¡erent parts of the
molecule, such as on the turn connecting s3C and s4C [18],
at the opposite end of the RCL [19], on the s2B and s3B
strands [20,21], may a¡ect its transformation from the active
to the latent form. A combination of changes of several res-
idues in di¡erent parts of the molecule gives an even more
pronounced stability [22]. It has also recently been shown that
Triton X-100 signi¢cantly accelerates conformational transi-
tions in PAI-1 [23,24]. In addition, PAI-1 is found in a cleaved
form, where it obviously has functioned as a substrate to tPA
rather than as an inhibitor [25^27]. The stability (i.e. conver-
sion of the active to the latent form) of PAI-1 is normally pH-
dependent. The native glucosylated protein is considerably
more stable at slightly decreased pH. Thus, its half-life at
pH 5.5 and 37‡C is about 16 h [28]. The decrease in pH
from neutral to slightly acidic is accompanied by protonation
of imidazole groups. It is therefore possible that one or several
histidine residues in PAI-1 might be involved in stabilizing the
active form. It was speculated that His143 might be responsible
for this e¡ect [29]. However, by introducing four di¡erent
mutations at this position in PAI-1, we recently demonstrated
that protonation of His143 is not directly involved in the pH-
dependent stability [30]. In our present work, we have system-
atically mutated the remaining 12 histidine residues to see if
any of these would be responsible for the observed stability of
PAI-1 at slightly acidic pH.
2. Materials and methods
2.1. Materials
In the PCR ampli¢cation, the thermostable DNA polymerase, Dy-
NAZyme, was from Finnzymes Oy (Espoo, Finland) and the Gene-
Amp PCR System 2400 was from Perkin-Elmer AB (Stockholm,
Sweden). PCR products were puri¢ed by QIAquick kit (Germany).
All restriction enzymes were purchased from New England BioLabs
Inc. (Beverly, MA, USA) and T4 DNA ligase was from Life Tech-
nologies AB (Ta«by, Sweden). In DNA sequencing, the BigDye Ter-
minator Cycle Sequencing Ready Reaction kit and the ABI PRISM
310 Genetic Analyzer were also from Perkin-Elmer AB. The vector,
pBV220, used to produce PAI-1 variants in Escherichia coli is a tem-
perature-inducible expression vector with VPR and VPL as promoters
[31]. In the protein puri¢cation, heparin-Sepharose CL-6B was from
Pharmacia AB (Uppsala, Sweden) and anhydrotrypsin agarose was
purchased from Sigma-Aldrich (Stockholm, Sweden). Imulyse PAI-1
kit and Chromolize PAI-1 activity kit (Biopool AB, Umeafi, Sweden)
were used to measure PAI-1 antigen and activity, respectively. Mela-
noma cell single-chain tPA was a kind gift from Biopool (courtesy of
Dr. Nils Bergsdorf).
2.2. Mutagenesis of PAI-1 cDNA
Site-directed mutations were introduced into PAI-1 cDNA by syn-
thesized oligonucleotides (primer 1^12, Table 1). The following muta-
tions were made, using a two-step PCR procedure [19], His2Thr,
His3Thr, His10Thr, His77Thr, His112Thr, His185Thr, His190Thr,
His219Thr, His229Thr, His261Thr, His316Thr and His364Thr. The
full-length PAI-1 cDNA with a XhoI site introduced at bp 871 by
silent mutation, encodes mature wild-type human PAI-1. This PAI-1
cDNA was cloned between the EcoRI and HindIII sites of pBV220
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(for mutants His2Thr, His3Thr, His10Thr and His77Thr, respectively)
or cloned between the EcoRI and HindIII sites of pUC19 (for the
remaining mutants). These two generated plasmids were used as tem-
plates in the ¢rst PCR. The mutation primers were used together with
a second primer, speci¢c for di¡erent mutations (primers 13^17, Table
1). The products were puri¢ed by agarose gel electrophoresis and
subsequently used as primers together with a second primer (primers
17^19, Table 1) in a second PCR. The EcoRI-HindIII fragment of
PAI-1 cDNA was used as a template. The products in the second
PCR were digested by EcoRI and XhoI (His2Thr, His3Thr, His10Thr
and His77Thr, respectively), SacI and XhoI (His112Thr, His185Thr,
His190Thr, His219Thr, His229Thr and His261Thr, respectively) or
SacI and BamHI (His316Thr and His364Thr respectively). The di-
gested products were subsequently used to replace the corresponding
fragment in PAI-1 cDNA in order to generate expression plasmids for
the PAI-1 mutants. The sequences in the mutated regions were con-
¢rmed by DNA sequencing, using primers 15 and 17, together with
one of the primers 20^23 (Table 1).
The mutation primers were designed to avoid the possibility of
unwanted mutations caused by an extra nucleotide added by DyNA-
Zyme to the 3P-terminus of DNA. The conditions used in the PCR
ampli¢cations were also optimized to diminish the errors caused by
the non-proof DNA synthesis of DyNAZyme.
2.3. Expression and puri¢cation of recombinant PAI-1
The PAI-1 variants were expressed and puri¢ed according to the
procedure described previously [19,32]. Brie£y, the expression plas-
mids based on pBV220 were induced to express recombinant PAI-1
proteins in the E. coli strain XL1 Blue at 42‡C in BHI medium con-
taining 50 mg/l ampicillin. After 4 h of cultivation at this temperature
(A650 = 1.5^1.6), the bacteria were harvested by centrifugation. The
pellet was quickly re-suspended in 0.05 mol/l sodium acetate bu¡er,
pH 5.5, containing 0.1 mol/l sodium chloride, 0.1 g/l Tween-80 and
0.5 g/l glycerol. Lysozyme digestion and sonication were used to dis-
rupt the bacteria. After another centrifugation for 30 min at 12 000Ug
and 4‡C, the supernatants of these PAI-1 variants were used as the
sources for chromatographic puri¢cation.
Puri¢cation by heparin-Sepharose CL-6B chromatography was per-
formed by equilibrating the column (bed volume about 5 ml) with
0.05 mol/l sodium acetate bu¡er, pH 5.5, containing 0.1 mol/l sodium
chloride and 0.1 g/l Tween-80. The unadsorbed proteins were washed
out by the same bu¡er and the PAI-1 adsorbed to the column was
eluted by a gradient of sodium chloride from 0.1 to 1.1 mol/l in 200
ml of the same acetate bu¡er. The fractions containing the highest
PAI-1 antigen concentrations were pooled and dialyzed against 0.15
mol/l sodium phosphate bu¡er, pH 6.6, containing 0.1 mol/l sodium
chloride. Subsequently, the samples were applied to an anhydrotryp-
sin agarose column (bed volume about 1.0 ml) equilibrated with the
same phosphate bu¡er [33]. The adsorbed material was eluted from
the column by 0.3 mol/l of arginine chloride dissolved in the same
bu¡er. The eluted PAI-1 variants were collected and stored frozen at
370‡C.
2.4. Determination of PAI-1 antigen and activity
PAI-1 antigen was measured by the Imulyse PAI-1 kit, using puri-
¢ed wild-type PAI-1 (wtPAI-1) produced in E. coli as a standard. The
absorbance coe⁄cient used was 7.7 for a 10 g/l wtPAI-1 solution [19].
PAI-1 activity was determined with the Chromolize PAI-1 kit.
2.5. Stability of PAI-1 mutants
The procedure to study the stability of PAI-1 variants was per-
formed as previously described [20]. PAI-1 stability was studied at
three di¡erent pH intervals; 5.5, 6.5 and 7.5. The temperature was
constantly kept at 37‡C. The bu¡er systems used were: 0.05 mol/l
sodium acetate bu¡er, pH 5.5, 0.05 mol/l sodium phosphate bu¡er
at pH 6.5 or at pH 7.5. The three bu¡ers also contained 0.1 mol/l
sodium chloride, 0.5 mg/ml bovine serum albumin and 0.1 g/l Tween-
80. The PAI-1 variants were diluted by these bu¡ers to a ¢nal con-
centration of 800 U/ml in a ¢nal volume of 1 ml. Samples of 100 Wl
were taken during the time interval from 0 to 8 h. The samples were
kept on ice until analysis.
2.6. Analysis of the reactions between PAI-1 variants and tPA by
SDS^PAGE
About 30 pmol of each PAI-1 variant was incubated with about 50
pmol of single-chain tPA at ambient temperature for 10 min. The
samples were analyzed by sodium dodecyl sulfate^polyacrylamide
gel electrophoresis (SDS^PAGE), performed with a Mini-PROTEAN
II Electrophoresis cell (Bio-Rad) according to the procedure described
by Laemmli [34]. A polyacrylamide gel concentration of 10% was used
and the gel was subsequently stained with Coomassie Brilliant Blue R-
250.
3. Results
3.1. Expression and puri¢cation of PAI-1 variants
Recombinant PAI-1 expressed in E. coli with the vector
pBV220 is found both soluble in the cytoplasm and precipi-
Table 1
Oligonucleotides for introducing mutations in PAI-1 cDNA and sequencing PAI-1 variants
No. Application Sequences of the oligonucleotides Position
1 His2Thr GG GGG ATG AGT CAC CAT GAA TTC C 317
2 His3Thr GA TGG GGG AGT GTG CAC CAT GAA T 320
3 His10Thr GA GGC CAG GGT AGC CAC GTA GGA 341
4 His77Thr AG CTC CTT GTA CAG AGT CCG AAG GGC 3248
5 His112Thr AG CCT GAA GAA GGT GGG CAT GAA GC 3350
6 His185Thr GAC TCC AGC ACC ACC CGT CGC CTC +544
7 His190Thr CGC CTC TTC ACC AAA TCA GAC GG +562
8 His219Thr ACG CCC GAT GGC ACT TAC TAC GAC +646
9 His229Thr GAA CTG CCC TAC ACT GGG GAC ACC +676
10 His261Thr CAG CTC ATC AGC ACC TGG AAA GG +772
11 His316Thr GC CTG CGC GAC GGT GAG AGG CTC T 3962
12 His364Thr GT TCC TGT GGG GTT AGT CCG AAC CA 31109
13 PCR GGA ACA ACG CAT AAC CCT GAA AG on pBV220
14 PCR GCA CCA TCC CCC ATC CTA +6
15 PCR, sequencing TCG TGA AGT CAG CCT GAA AC 3925
16 PCR GGT CAG GGT TCC ATC ACT ACT T 31148
17 PCR, sequencing GAG AAA CCC AGC AGC AGA T +158
18 PCR CCC AGG TTC TCG AGG GGC TTC CTG AG 3884
19 PCR GTT TTC CCA GTC ACG AC. on pUC19
20 sequencing AG CTC CTT GTA CAG AGT CCG AAG GGG 3248
21 sequencing TGT AAA ACG ACG GCC AGT GAA GAA GTG GGG CAT GAA 3363
22 sequencing CAA CTT GCT TGG GAA AGG AG +450
23 sequencing TGT AAA ACG ACG GCC AGT GAC CTC AGG AAG CCC CTC +856
The sequences are shown from 5P to 3P. The mutated nucleotides are printed in bold in all primers and the mutated codons are underlined. Lo-
cation of each 5P nucleotide is given and the signs + and 3 indicate the coding and antisense strands, respectively.
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tated in inclusion bodies. Since there is a higher risk that the
protein in the inclusion bodies is denatured, the soluble pro-
teins in the cytoplasm have been used as the source for protein
puri¢cation. Most of the PAI-1 variants were expressed in a
soluble form in quite a high yield. When His364 was changed
to Thr, the soluble form of the protein repetitively displayed a
somewhat lower yield in the cytoplasm than did the other
PAI-1 variants. Most PAI-1 variants, including wtPAI-1,
were eluted from the heparin-Sepharose column at a concen-
tration of about 0.73 mol/l of sodium chloride. The four var-
iants His3Thr, His77Thr, His112Thr and His229Thr were
eluted somewhat earlier during the heparin-Sepharose chro-
matography (at 0.62, 0.59, 0.63 and 0.63 M NaCl, respec-
tively), suggesting a slightly decreased a⁄nity for heparin.
3.2. Inhibitory activity of PAI-1 variants
The speci¢c activities of the di¡erent PAI-1 variants puri-
¢ed from anhydrotrypsin agarose are shown in Table 2. The
data were obtained by dividing the activity values with the
protein concentration calculated from the absorbance values
(280 nm). Calculation of speci¢c activities by dividing activity
and antigen concentrations gave very similar results (data not
shown). wtPAI-1 had an inhibitory activity of about 1.1U106
U/mg. As can be seen, most PAI-1 variants show a small
decrease in activity as compared to wtPAI-1. The speci¢c
activity for the mutant His364Thr was only 45% of the activ-
ity of wtPAI-1. However, as can be seen in SDS^PAGE (Fig.
1) this variant to a large extent forms a stable complex with
tPA. The somewhat decreased activity is most likely due to
the presence of impurities in the PAI-1 preparation, supported
by PAI-1 antigen measurements.
3.3. Reactions of the PAI-1 variants with tPA
As visualized by SDS^PAGE, all of the PAI-1 variants
puri¢ed by anhydrotrypsin agarose a⁄nity chromatography
formed a complex with single-chain tPA when incubated
with a slight excess of this enzyme (Fig. 1). A small amount
of the cleaved form of PAI-1 is seen after the incubation, most
likely representing the substrate form of the inhibitor.
3.4. Stability of the PAI-1 variants
The stability represented by the decline in activity measured
as half-lives of the PAI-1 variants is shown in Table 3. Most
PAI-1 variants follow the same stability pattern as wtPAI-1,
with longer half-lives as pH is decreased. The PAI-1 mutants
His229Thr and His316Thr di¡er from wtPAI-1 by having a
less pronounced pH-dependent stability. His2Thr, His10Thr,
His112Thr and His219Thr have slightly longer half-lives at
pH 6.5 than wtPAI-1 (12.3, 10.6, 12.0 and 15.6 h, respec-
tively). His112Thr and His219Thr have slightly decreased
half-lives at pH 5.5 (around 20 h for both). Two of the mu-
tants, His185Thr and His190Thr, show largely decreased half-
lives at all pH values studied, as compared to wtPAI-1. Most
interestingly, the PAI-1 mutant His364Thr displayed an al-
most complete £at pro¢le regarding stability at the three dif-
ferent pH’s studied. Indeed this ¢nding supports the idea that
protonation of this histidine residue participates in the normal
stabilization of the PAI-1 molecule.
4. Discussion
The PAI-1 molecule, native or recombinant, is synthesized
as a fully active molecule but converts rapidly to an inactive
so-called latent form at physiological conditions. The half-life
for this transition is about 2 h at neutral pH and 37‡C [10,11].
The mechanism is not fully understood but it seems that in-
sertion of the RCL into the A L-sheet plays an important role
[17]. In this way the bait peptide bond becomes inaccessible to
plasminogen activators. PAI-1 is signi¢cantly more stable at
Table 2
Speci¢c activity of all the PAI-1 variants
PAI-1 mutants Speci¢c activity (U106 U/mg)
wtPAI-1 1.08 þ 0.09
His2Thr 0.88 þ 0.06
His3Thr 0.79 þ 0.13
His10Thr 0.86 þ 0.06
His77Thr 0.55 þ 0.06
His112Thr 0.76 þ 0.10
His143Thra 0.98 þ 0.15
His185Thr 0.88 þ 0.14
His190Thr 0.86 þ 0.16
His219Thr 1.24 þ 0.08
His229Thr 0.84 þ 0.03
His261Thr 1.14 þ 0.03
His316Thr 0.80 þ 0.06
His364Thr 0.49 þ 0.05
The data were obtained from at least three separate experiments
and expressed as mean þ S.D.
aPublished previously, see [30].
Fig. 1. SDS^PAGE of mixtures of the PAI-1 variants and tPA. About 30 pmol of each PAI-1 variant was mixed with about 50 pmol of sin-
gle-chain tPA in a phosphate bu¡er of pH 7.3 (in a ¢nal volume of 100 Wl). After 10 min of incubation at ambient temperature, 20 Wl of the
mixture was applied to the gel and analysis was performed as described in Section 2.
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slightly acidic pH [19,28]. Kvassman et al. reported that the
acidic stabilization was due to the protonation of a single
group with a pKa value of 7.6 [29]. They proposed that
His143 in helix F, situated in the vicinity of the A L-sheet in
the three-dimensional structure of PAI-1, could be involved.
However, recently we were able to demonstrate that His143 is
not responsible for the pH-dependent stability, since substitu-
tion of this histidine residue by threonine did not cause a
decreased stability of PAI-1 at low pH [30]. In the present
study we have substituted the remaining 12 histidine residues
in PAI-1 by threonine, to see if any of these are responsible
for the observed pH-dependence. If the protonated form of a
histidine group would be involved in the stabilization of the
active inhibitor, then exchange of this positively charged res-
idue towards an uncharged residue (such as Thr) is expected
to cause a decreased stability at low pH. We have previously
found that modi¢cation of His229 to either Asp or Phe re-
sulted in a clearly decreased pH-dependence regarding PAI-
1 stability [21]. In our present work, most of the mutants did
not display any signi¢cant changes in the pH-dependent
stability. Most interestingly, however, the mutant His364Thr
did not display any such pH-dependent stability. The half-life
for the active to latent transformation of this mutant was
found to be identical at pH 7.5 and 5.5. At pH 6.5 it was
only marginally increased. Further, the stability of this mutant
seems to be somewhat decreased over the whole pH range, as
compared to wtPAI-1 at pH 7.5. From these data it seems
likely that the protonation of His364 may be involved in the
physiological stabilization of PAI-1 and that it indeed could
be responsible for the increased stability of PAI-1 at slightly
acidic pH. Crystallographic data have suggested that His364,
close to the COOH-terminal end of the protein, is situated in
close vicinity to the B L-sheet, just beyond the A L-sheet
where insertion of the RCL is believed to take place. Thus
it is plausible that a positive charge at residue 364 might
partially prevent this insertion.
The results in this study are achieved with non-glycosylated
mutants produced in E. coli, whereas the native PAI-1 mole-
cule contains more than 10% carbohydrate. Although wtPAI-
1 produced in E. coli to a large extent has very similar proper-
ties as ‘native’ glycosylated PAI-1, we cannot be absolutely
certain that our ¢ndings can be fully extrapolated to glycosy-
lated PAI-1.
Another ¢nding in the present work is that some of the
PAI-1 variants with modi¢ed histidine residues displayed a
slightly decreased binding to heparin (His3Thr, His77Thr,
His112Thr and His229Thr). In the antithrombin molecule,
the primary binding site for heparin has been found to exist
on helix D [35]. Previously it has been suggested that the
positively charged residues Lys65, Lys69, Arg76, Lys80, Lys88
[36] and Arg115, Arg118 [19] are involved in the binding of
PAI-1 to heparin. From the three-dimensional structure of
PAI-1 it seems that residues His3, His77 and His112 are situ-
ated on or in close vicinity to helix D and it is possible that
these residues also are involved in the binding of PAI-1 to
heparin.
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